https://doi.org/10.4081/hmr.v1i6.674

Deferasirox: una nuova opzione terapeutica per il trattamento del sovraccarico marziale anche in età pediatrica

Vol. 1 No. 6: XXXIV Congresso Nazionale Società Italiana Ematologia Oncologia Pediatrica
Published: June 22, 2009
Abstract Views: 135
PDF: 255
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

GL Forni
support@pagepress.org
Il deferasirox (Exjad®, ICL670) è un chelante orale del ferro appartenente ad una nuova classe di chelanti tridentati: I bis-idrossifenil-triazoli sostituiti.1 Il farmaco si somministra in monodose giornaliera e l’eliminazione del ferro avviene prevalentemente per via fecale. L'emivita del farmaco è stata calcolata di 12-13 ore.2-3 I suo impiego è stato approvato da FDA ed EMEA come farmaco di prima linea nel trattamento del sovraccarico di ferro cronico conseguente a terapia trasfusionale in pazienti di età ≥2aa.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Forni, G. (2009). Deferasirox: una nuova opzione terapeutica per il trattamento del sovraccarico marziale anche in età pediatrica. Hematology Meeting Reports (formerly Haematologica Reports), 1(6). https://doi.org/10.4081/hmr.v1i6.674
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).